CLINICAL PREDICTORS OF CARDIOVASCULAR OUTCOMES IN PATIENTS ON CELECOXIB, IBUPROFEN, AND NAPROXEN

Haris Riaz,Grant W. Reed,Qiuqing Wang,Lisa Wisniewski,Kathy Wolski,A.M. Lincoff,Steven E. Nissen

CLINICAL PREDICTORS OF CARDIOVASCULAR OUTCOMES IN PATIENTS ON CELECOXIB, IBUPROFEN, AND NAPROXEN

2019

Haris Riaz
Grant W. Reed
Qiuqing Wang
Lisa Wisniewski
Kathy Wolski
A.M. Lincoff
Steven E. Nissen

The PRECISION trial established the cardiovascular (CV) safety of celecoxib was non-inferior to ibuprofen and naproxen in patients with non-steroidal anti-inflammatory drug (NSAID) dependent arthritis. Herein, we describe the clinical predictors of CV events in PRECISION. 23,953 patients dependent

Keywords:

Drug
Celecoxib
Naproxen
Cardiology
Arthritis
Diabetes mellitus
Medicine
Internal medicine
Ibuprofen
in patient
cardiovascular outcomes

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations